Francis Esteban Matos: Final Debarment Order
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Francis Esteban Matos for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Matos was convicted of a felony under Federal law. The factual basis supporting Mr. Matos's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Matos was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of May 18, 2026 (more than 30 days after receipt of the notice), Mr. Matos had not responded. Mr. Matos's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Read the official notice →Source: Federal Register (FDA/USDA food labeling) · US Government work (public domain). This is a short, attributed summary; the full authoritative text lives on the authority’s own site. LabelYog does not author or endorse it — confirm compliance against the destination market’s official source.
More from United States
- Reducing Barriers to Medical Use Licensing regulatory
- Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Radioactive Drug Research Committees regulatory
- Notice of Actions in Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure of Each Economy To Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced With Forced Labor regulatory
- Statement of Organization, Functions, and Delegations of Authority regulatory
- Generic Drug User Fee Rates for Fiscal Year 2027 regulatory
- Outsourcing Facility Fee Rates for Fiscal Year 2027 regulatory
What this means for your label
A notice like this changes what a pack must carry. These are the rules we build against, starting with US FDA.